The case of acupuncture for chronic low back pain: When efficacy and comparative effectiveness conflict

This critical analysis examines a fascinating paradox in acupuncture research: when efficacy (superiority over placebo) and clinical effectiveness (benefits compared with established treatments) come into conflict. The authors analyzed two large clinical trials investigating acupuncture for chronic low back pain, a condition that affects millions worldwide.

The German GERAC trial enrolled 1,162 patients randomized to true acupuncture, sham acupuncture, or conventional medical care. After 6 months, positive clinical response rates were practically identical between true acupuncture (47.6%) and sham (44.2%), with no statistically significant difference. However, both were dramatically superior to conventional care (27.4%). The American trial replicated these findings in 638 patients, showing that individualized, standardized, and simulated acupuncture produced similar improvements on the Roland-Morris scale (4.4-4.5 points), all superior to usual care (2.1 points).

These results create an interpretive dilemma: acupuncture does not demonstrate specific efficacy (it does not outperform placebo), but it shows clear clinical effectiveness (it outperforms conventional treatments). A systematic review of 23 clinical trials with 6,359 patients confirmed this consistent pattern.

The cost-effectiveness analysis adds an important dimension. German studies with 8,300 patients demonstrated that the incremental cost of acupuncture per quality-adjusted life year was below €13,000, under the international cost-effectiveness threshold. British studies confirmed these favorable estimates.

This evidence influenced significant health policy. In 2006, Germany approved reimbursement for acupuncture for chronic low back pain. In 2009, the UK's NICE recommended that healthcare providers offer acupuncture to patients with chronic low back pain. In the United States, the American College of Physicians recommends it as a second-line therapy.

The implications are profound for evidence-based medicine. Traditionally, superiority over placebo was considered the gold standard for treatment approval. However, these guidelines suggest a paradigm shift in which clinical effectiveness and cost-effectiveness can outweigh the need for specific efficacy, especially when safe and reliable options are limited.

This case illustrates the evolution of contemporary medical thinking, in which considerations of patient-centered care and economic realities are beginning to influence the legitimacy of interventions as much as traditional research criteria. For chronic low back pain, where conventional therapeutic options often show limitations, acupuncture emerges as a valid alternative based on demonstrable clinical benefits, regardless of the specific mechanisms involved.